Epitalon vs Humanin
Both Epitalon and Humanin are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
Epitalon
Evidence C+Epitalon (Epithalon, AEDG)
A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.
View full Epitalon profile →Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Side-by-Side
| Attribute | Epitalon | Humanin |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — Russian-origin research peptide | Not FDA-approved — mitochondrial-derived peptide research compound |
| Typical Dose | 5–10 mg daily for 10–20 days, cycled (subcutaneous) | Research range: 0.5–1 mg subcutaneous (rare clinical use) |
| Clinics Indexed | 47 | 5 |
| Categories | anti-aging, longevity | mitochondrial, longevity, neuroprotection |
Key reported benefits — Epitalon
- ✓Telomerase upregulation (preclinical)
- ✓Sleep/circadian normalization
- ✓Anti-aging signals
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.